NeuBase Therapeutics to Participate in Upcoming Investor Conferences in May 2021

Rhea-AI Summary

NeuBase Therapeutics, Inc. (Nasdaq: NBSE) announced participation in two major events in May 2021. CEO Dietrich A. Stephan will engage in a virtual fireside chat at the RBC Capital Markets Virtual Global Healthcare Conference on May 19 at 11:30 a.m. ET. Additionally, he will present a corporate overview at the Oppenheimer Rare & Orphan Disease Summit on May 21. NeuBase focuses on developing precision genetic medicines targeting genetic diseases at the DNA or RNA level, aiming to address significant health challenges.

RBC Capital Markets Virtual Global Healthcare Conference Fireside Chat at 11:30 a.m. ET on May 19

Oppenheimer Rare & Orphan Disease Summit presentation on May 21

PITTSBURGH, May 14, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase”), a biotechnology company accelerating the genetic revolution with a new class of precision genetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will participate in a virtual fireside chat at the RBC Capital Markets Virtual Global Healthcare Conference, as well as present a corporate overview and business update at the Oppenheimer Rare & Orphan Disease Summit, which are both being held in May 2021.

Conferences Details:

Event:	RBC Capital Markets Virtual Global Healthcare Conference
Format:	Fireside Chat
Date:	Wednesday, May 19th
Time:	11:30 a.m. ET
Location:	Webcast Link – or at the company’s website (click here)
Event:	Oppenheimer Rare & Orphan Disease Summit
Format:	Presentation
Date:	Friday, May 21st
Location:	Webcast Link – or at the company’s website (click here)

About NeuBase Therapeutics
NeuBase is accelerating the genetic revolution by developing a new class of precision genetic medicines which can be designed to increase, decrease, or change gene function, as appropriate, to resolve genetic defects that drive disease. NeuBase’s targeted PATrOL™ therapies are centered around its proprietary drug scaffold to address genetic diseases at the DNA or RNA level by combining the highly targeted approach of traditional genetic therapies with the broad organ distribution capabilities of small molecules. With an initial focus on silencing disease-causing mutations in debilitating neurological, neuromuscular, and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions. To learn more, visit www.neubasetherapeutics.com.

NeuBase Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors, LLC
Daniel@lifesciadvisors.com 
OP: (617) 430-7576

NeuBase Media Information:

Jessica Yingling, Ph.D.
Little Dog Communications Inc.
(858) 344-8091
jessica@litldog.com

FAQ

What is NeuBase Therapeutics' participation in the RBC Capital Markets Virtual Global Healthcare Conference?

NeuBase Therapeutics will engage in a virtual fireside chat at the RBC Capital Markets Virtual Global Healthcare Conference on May 19, 2021.

When is the Oppenheimer Rare & Orphan Disease Summit presentation?

The Oppenheimer Rare & Orphan Disease Summit presentation is scheduled for May 21, 2021.

Who will represent NeuBase at the upcoming conferences?

Dietrich A. Stephan, Ph.D., CEO of NeuBase, will represent the company at both conferences.

What is the focus of NeuBase Therapeutics?

NeuBase is focused on developing a new class of precision genetic medicines targeting genetic diseases by modifying gene function.

Where can I find more information about NeuBase Therapeutics?

More information can be found on NeuBase's website at www.neubasetherapeutics.com.